New drug combo shows promise for tough lung cancer

NCT ID NCT03392246

Ongoing Disease control Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jan 11, 2026 · Last updated May 01, 2026 · Updated 18 times

Summary

This study tests whether combining two targeted drugs, osimertinib and selumetinib, works better than standard care for people with advanced EGFR-mutant non-small cell lung cancer. About 25 participants will receive the combination to see how many respond and how long the cancer stays controlled. The goal is to improve outcomes without a cure, as ongoing treatment is needed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Duke University

Durham, North Carolina, 27710, United States
Massachusetts General Hospital

Boston, Massachusetts, 02214, United States

Conditions

Explore the condition pages connected to this study.

NON SMALL CELL LUNG CANCER